Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients
Status:
Active, not recruiting
Trial end date:
2022-10-07
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate the superiority of subcutaneous erenumab compared to
oral prophylactic(s) on sustained benefit defined as % subjects completing one-year on the
randomized treatment and achieving at least a 50% reduction from baseline in monthly migraine
days at month 12.